Hans Clevers, who now leads Pharma Research and Early Development (pRED) at Roche, has spent decades pioneering breakthrough technologies that bridge the gap between academic research and pharmaceutical development. His groundbreaking work on organoids – tissues derived from stem cells that mimic lab-grown organs – is revolutionizing drug development and personalized medicine.
From Stem Cells To Organoids: Roche’s Hans Clevers’s Quest To Transform Drug Development
This is Part 1 of a 2-part profile of Hans Clevers, Head of Pharma Research and Early Development at Roche.
More from Leadership
• By
Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.
• By
In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.
• By
The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
• By
Top 30 leaders: see the list of industry influencers highlighted in the sixth edition of In Vivo's Rising Leaders series.
More from C-Suite Speaks
• By
With British Science Week upon us, how are UK life science firms faring, what’s the outlook for the future, and how can the environment be improved to better foster innovation – and make it pay?
• By
Rentschler Biopharma CEO Benedikt von Braunmühl tells In Vivo about the CDMO's strategic decision to exit the cell and gene therapy manufacturing space.
• By
Twenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip.